Press release
Global Connective Tissue Disease Treatment Market Expansion at 6.1% CAGR, Valued at $31.11 Billion by 2029
Connective Tissue Disease Treatment
What Are the Connective Tissue Disease Treatment Market Size Forecast for 2025?
In recent years, the market size for connective tissue disease treatments has experienced robust growth. The market projection indicates an increase from $23.08 billion in 2024 to $24.55 billion in 2025, signifying a compound annual growth rate (CAGR) of 6.3%. This upward trend in the historic period is primarily due to factors such as the growing instances of autoimmune disorders, heightened awareness regarding early diagnosis, enhancements in healthcare infrastructure in the developing regions, increased utilization of biologics, along with an expansion in insurance coverage dedicated to managing chronic diseases.
What Is the Market Size Outlook for Connective Tissue Disease Treatment Until 2029?
The market for treatment of connective tissue diseases is set for strong expansion in the coming years, with projections indicating a growth to $31.11 billion by 2029 with a compound annual growth rate (CAGR) of 6.1%. Factors contributing to this predicted growth during the forecast period include an aging population, higher R&D investment from pharmaceutical firms, increasing demand for individualized medicine, a growing line of specific therapies, and a focus on care models that prioritize the patient. The forecast period will also witness trends such as progress in monoclonal antibody therapies, implementation of telemedicine for disease tracking, a move towards biologics and biosimilars, creation of multi-target drug schemes, and increased collaboration between educational and clinical research organizations.
Explore The Complete Report Now:
https://www.thebusinessresearchcompany.com/report/connective-tissue-disease-treatment-global-market-report
What Are the Major Factors Driving Demand in the Connective Tissue Disease Treatment Market?
The upward trend in autoimmune diseases is forecasted to fuel the expansion of the connective tissue disease treatment market. Autoimmune diseases are conditions where the body's immune system erroneously targets its own healthy tissues and organs. The escalating numbers of autoimmune diseases are chiefly due to a blend of genetic sensitivity, making certain individuals more inclined to immune system dysfunctions, and environmental elements like infections, diet, stress, and exposure to toxins, which can provoke or intensify these disorders. Treatment for connective tissue disease aims at the root immune system irregularity causing inflammation and tissue harm, consequently relieving symptoms, halting disease development, and enhancing the general quality of life for patients suffering from conditions such as lupus, rheumatoid arthritis, and scleroderma. For instance, the Versorgungsatlas.de, a German online platform that showcases healthcare, reported in November 2024 that 6,304,340 out of 73,241,305 insured individuals were identified with a minimum of one autoimmune disease in 2022, resulting in a crude prevalence rate of 8.61%. Hence, the escalating incidence of autoimmune diseases is stimulating the expansion of the connective tissue disease treatment market.
Get Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=25726&type=smp
How Are End-Use Segments Shaping the Connective Tissue Disease Treatment Market Outlook?
The connective tissue disease treatment market covered in this report is segmented -
1) By Drug Class: Anti-Inammatory Drugs, Immunosuppressants, Biologics And Targeted Therapy, Disease-Modifying Anti-Rheumatic Drugs (DMARDs), Other Drug Classes
2) By Disease Type: Systemic Lupus Erythematosus (SLE), Rheumatoid Arthritis (RA), Scleroderma, Dermatomyositis, Mixed Connective Tissue Disease (MCTD), Polymyositis, Sjögren's Syndrome, Vasculitis, Antiphospholipid Syndrome (APS)
3) By Route Of Administration: Oral, Injectable, Topical
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
5) By End-User: Hospitals, Clinics, Homecare Settings
Subsegments:
1) By Anti-Inflammatory Drugs: Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Systemic Corticosteroids
2) By Immunosuppressants: Calcineurin Inhibitors, Mammalian Target Of Rapamycin (mTOR) Inhibitors, Antimetabolites, Alkylating Agents
3) By Biologics And Targeted Therapy: Tumor Necrosis Factor (TNF) Inhibitors, Interleukin-6 (IL-6) Inhibitors, B-Cell Inhibitors, T-Cell Co-Stimulation Modulators, Janus Kinase (JAK) Inhibitors
4) By Disease-Modifying Anti-Rheumatic Drugs (DMARDs): Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (DMARDs), Biologic Disease-Modifying Anti-Rheumatic Drugs (DMARDs), Targeted Synthetic Disease-Modifying Anti-Rheumatic Drugs (DMARDs)
5) By Other Drug Classes: Analgesics, Antimalarial Drugs, Antibiotics, Monoclonal Antibodies
What Are the Strategic Trends Transforming the Connective Tissue Disease Treatment Market Landscape?
Prominent enterprises in the connective tissue disease treatment market are concentrating on executing clinical trials to devise innovative therapies, including allogeneic CAR-NK cell therapy, for improved effectiveness and resolving unfulfilled requirements in autoimmune disorders. The allogeneic CAR-NK cell therapy is a procedure that utilizes normal killer (NK) cells from healthy donors, genetically equipped with a chimeric antigen receptor (CAR) to target and annihilate cells causing the disease. It functions by amplifying the immunological system's capacity to terminate disease-causing B-cells engaged in autoimmune diseases, providing a possibly safer and more attainable alternative compared to classic cell therapies. For instance, in July 2024, Nkarta Inc., a clinical-stage biotechnology establishment based in the US, started the Ntrust-1 clinical trial to investigate NKX019, a study-based allogeneic CAR-NK cell therapy, for treating lupus nephritis and received FDA approval to commence a distinct trial (Ntrust-2) for systemic sclerosis, idiopathic inflammatory myopathy, and ANCA-associated vasculitis. This is done in hopes of addressing substantial unfulfilled requirements in autoimmune disorders by enhancing the safety, availability, and effectiveness of cell-based therapies using genetically engineered NK cells targeting CD19-expressing B-cells selectively.
Customize Your Insights And Get The Full Report Here:
https://www.thebusinessresearchcompany.com/customise?id=25726&type=smp
Who Are the Prominent Companies in the Connective Tissue Disease Treatment Market by ?
Major companies operating in the connective tissue disease treatment market are Pfizer Inc., F. Hoffmann-La Roche AG, AbbVie Inc., Sanofi S.A., Bristol Myers Squibb Company, AstraZeneca PLC, Novartis AG, GlaxoSmithKline (GSK) PLC, Eli Lilly and Company, Amgen Inc., Biogen Inc., Vertex Pharmaceuticals, UCB S.A., Hikma Pharmaceuticals PLC, Innovent Biologics Inc., RemeGen Co. Ltd, Kymera Therapeutics, Adicet Bio, Equillium Inc., Stem Cell Care India.
Which Region Is Expected to See the Highest CAGR in the Connective Tissue Disease Treatment Market?
North America was the largest region in the connective tissue disease treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the connective tissue disease treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
#Reach Out to Us#
Speak With Our Expert:
Saumya Sahay
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: saumyas@tbrc.info
The Business Research Company - www.thebusinessresearchcompany.com
Follow Us On:
• LinkedIn: https://in.linkedin.com/company/the-business-research-company
Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.
Contact Us
Saumya Sahey
Europe: +44 7882 955267,
Asia: +44 7882 955267 & +91 8897263534,
Americas: +1 310-496-7795
Email: saumyas@tbrc.info
Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Global Connective Tissue Disease Treatment Market Expansion at 6.1% CAGR, Valued at $31.11 Billion by 2029 here
News-ID: 4157480 • Views: …
More Releases from The Business Research Company
Ammonium Sulfate Market on Path to Hit $5.99 Billion by 2029 at 9.6% CAGR
Use ONLINE30 for 30% savings on global market reports and stay on top of tariff updates, market trends, and economic shifts worldwide.
Ammonium Sulfate Market Outlook: What Size And CAGR Are Anticipated By 2025?
The market size for ammonium sulfate has seen substantial growth in the past few years. The market is set to increase from a value of $3.88 billion in 2024 to $4.16 billion in 2025, with a compound annual…
Global Biodegradable Hemostat Market Expansion at 10.9% CAGR, Valued at $1.48 Bi …
Use ONLINE30 for 30% savings on global market reports and stay on top of tariff updates, market trends, and economic shifts worldwide.
What Are the Biodegradable Hemostat Market Size Forecast for 2025?
The market size for biodegradable hemostats has experienced striking growth in the past few years. From being valued at $0.88 billion in 2024, it is predicted to grow to $0.97 billion in 2025, attaining a compound annual growth rate (CAGR)…
Aerospace Interior Adhesive Market to Record 7.8% CAGR Growth Through 2029 | Glo …
Use ONLINE30 for 30% savings on global market reports and stay on top of tariff updates, market trends, and economic shifts worldwide.
Aerospace Interior Adhesive Market Outlook: How is the Market Expected to Grow by 2025?
Recent years have seen robust growth in the aerospace interior adhesive market. The market is projected to expand from $1.27 billion in 2024 to $1.34 billion in 2025, posting a compound annual growth rate (CAGR) of…
Aseptic Connectors And Welders Market Expansion Outlook: $3.96 Billion in 2029
Get 30% off global market reports with code ONLINE30 and keep ahead of tariffs, macro trends, and worldwide economic developments.
What Is the Projected CAGR for the Aseptic Connectors And Welders Market from 2024 to 2025?
In recent times, there has been a swift surge in the size of the aseptic connectors and welders market. The market is forecasted to escalate from $1.72 billion in 2024 to $2.04 billion in 2025, representing…
More Releases for Disease
Protheragen Announces Disease Model Development Services to Enhance Rare Disease …
Protheragen announced the release of its disease model development services provided to enhance rare disease research. With an increasing focus on rare diseases and the need for tailored research models, Protheragen is dedicated to providing cutting-edge solutions to support this important area of medical research.
Rare diseases, which affect a small percentage of the population, pose unique challenges for researchers due to their limited understanding and lack of available treatment options.…
Biopharmaceutical Fermentation Market 2022 | Growing Morbidity of Genetic Diseas …
According to Precision Business Insights (PBI), the latest report, the biopharmaceutical fermentation market is expected to be valued at USD 10,302.1 million in 2022, growing at a 4.7% CAGR from 2022 to 2028. The growing prevalence of chronic illness, cancer, cardiac diseases, infectious diseases, antibiotic resistance, autoimmune diseases, etc., globally causes the leaning toward biopharmaceutical products, which show promising results in the research studies. Moreover, new findings by the…
Global Inflammatory Bowel Disease (IBD) Market Key Players Analysis, Disease Ind …
Global Inflammatory Bowel Disease (IBD) Market, valued at USD 210.5 Billion in the year 2020 has been driven by factors such as the increasing prevalence of Ulcerative Colitis and Crohn’s Disease, advances in medical technology, government support for inflammatory bowel disease treatment research, and the ubiquity of anxiety and depression. Moreover, factors such as the irregular food habits, unhealthy lifestyle of people, increased level of pollution and increase in alcohol…
Moyamoya Disease Market - A Scientometric Assessment of Disease During 2018-23
Market Highlight:
Moyamoya disease (MMD) is a chronic, cerebrovascular disease characterized by progressive stenosis in the internal carotid artery and an abnormal vascular network at the base of the brain. The stroke is one of the significant symptoms of moyamoya disease, which further leads to paralysis of the face, arms, and legs, loss of speech, and temporary loss of neurologic function of body parts, visual disturbances, headaches, developmental delay, and…
Refsum Disease Industry An Overview of A New Disease - 2018
"Refsum Disease" is a genetic disorder which is inherited as an autosomal recessive trait. The condition is characterized by progressive loss of vision (retinitis pigmentosa), failure of muscle coordination (ataxia), degenerative nerve disease (peripheral neuropathy), and dry, rough, scaly skin (ichthyosis). The accumulation of fatty acid (phytanic acid) in blood plasma and tissues is the main cause of refsum disease. This occurs due to malfunction of the enzyme producing gene…
Chagas Disease (Infectious Disease) Pipeline Forecast Report, H1, 2017 [MRH]
Market Research Hub's Pharmaceutical and Healthcare latest pipeline guide Chagas Disease - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Chagas Disease Market (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and…
